Últimas noticias sobre SAB Biotherapeutics (NASDAQ:SABS) Bolsa

SAB Biotherapeutics

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

SAB Biotherapeutics Inc

News

Guidance

RYAM

Rayonier Advanced Materials Reports Preliminary 2024 Net Sales Of $1.639B (Est $1.626B), A Decline Of $4M From Prior Year

Several AI-linked stocks are trading higher in Monday&#8217;s after-hours session following Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) shares rocketing higher on based on blowout earnings. Here&#8217;s what <a href="https://www.benzinga.com/news/earnings/25/02/43449486/palantir-q4-earnings-revenue-beat-eps-beat-us-revenue-up-52-customer-count-up-43-strong-guidance-this-is-a-new-phase-unlike-anything-that-has-come-before">you need to know</a>.
What Happened With PLTR: Palantir beat analyst estimates on the top and bottom lines, reporting fourth-quarter revenue of $827.52 million and earnings of 14 cents per share.
Total revenue grew 36% year-over-year driven by strong growth in the U.S. of 52%. U.S. Commercial revenue jumped 64% year-over-year and U.S. Government revenue increased 45% year-over-year.
Palantir's customer count grew 43% year-over-year. The company delivered $517 million in adjusted free cash flow and ended the quarter with $5.2 billion of cash, equivalents and short-term U.S. treasury securities.
"We are still in the earliest stages, the beginning of the first act, of a revolution that will play out over years and decades," Palantir CEO Alex Karp said in a letter to shareholders.&nbsp;
"This is not an incremental advance or marginal acceleration of our business. This is a new phase. And the momentum we are seeing across sectors, both commercial and government, is unlike anything that has come before."
Check This Out: <a href="https://www.benzinga.com/news/earnings/25/02/43449486/palantir-q4-earnings-revenue-beat-eps-beat-us-revenue-up-52-customer-count-up-43-strong-guidance-this-is-a-new-phase-unlike-anything-that-has-come-before">Palantir Q4 Earnings: Revenue Beat, EPS Beat, US Revenue Up 52%, Customer Count Up 43%, Strong Guidance</a>
The upside surprise and optimistic commentary from the company appears to be driving other AI-related names higher after the bell. 
Tempus AI Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) has seen increased attention in recent weeks after former House Speaker Nancy Pelosi disclosed the purchase of several call options. Tempus AI shares were up more than 7% in extended trading at last check.
Other AI-related names including C3.ai Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>), BigBear.ai Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) and SoundHound AI Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) were also moving higher following Palantir&#8217;s quarterly report. C3.ai shares were up about 4.5%, BigBear.ai shares were up about 5.5% and SoundHound shares were up about 2%.
NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), which has been the biggest beneficiary of the AI boom to date, was also moving higher, last up about 1.35% in after-hours trading. Palantir shares were up more than 22% in after-hours at the time of publication Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/01/43402466/nancy-pelosi-pick-tem-stock-exciting-unpredictable-volatility">Options Corner: Tempus AI Stock Soars On Nancy Pelosi&#8217;s Call Options — But Should Investors Follow?</a></li>
</ul>
This illustration was generated using artificial intelligence via Midjourney.

Earnings

After-Hours Center

Movers

Tech

BBAI

NVDA

PLTR

SOUN

AI Stocks Are Rallying After The Bell: What's Going On?

Ameriprise Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>) has outperformed the market over the past 10 years by 3.51% on an annualized basis producing an average annual return of 14.71%. Currently, Ameriprise Finl has a market capitalization of $51.67 billion. 
Buying $100 In AMP: If an investor had bought $100 of AMP stock 10 years ago, it would be worth $398.78 today based on a price of $537.12 for AMP at the time of writing.
<h3>Ameriprise Finl's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738622708_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

"Over the last few years, we proactively moved our U.S.-bound camera production outside of China, which has significantly reduced the impact of tariffs," said Brian McGee, CFO and COO of GoPro. "We are continuously evaluating and optimizing our supply chain to improve delivery of our products at lower cost."

GPRO

GoPro Says Its Diversified Supply Chain Mitigates Potential Impact Of US Tariffs; Does Not Expect US Consumer Pricing Or Gross Margin To Be Materially Affected By Recent Tariff Announcements

Nauticus completed assembly and the first phase of acceptance testing at its Houston facility in January. This second Aquanaut vehicle is now in Louisiana undergoing the next phase of acceptance testing.
The vehicle should complete the required pool testing this month. Once completed, the vehicle will move to the final phase of testing in open water off the southern coast of the United States. Nauticus is targeting completion of all acceptance testing for this vehicle within the first quarter of 2025.

KITT

Nauticus Robotics Reports Assembly Completion Of Its Second Flagship Underwater Vehicle, Aquanaut Mark 2; Targets Completion Of All Acceptance Testing For This Vehicle Within Q1 Of 2025

Celsius Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) has outperformed the market over the past 10 years by 43.64% on an annualized basis producing an average annual return of 54.84%. Currently, Celsius Holdings has a market capitalization of $5.62 billion. 
Buying $1000 In CELH: If an investor had bought $1000 of CELH stock 10 years ago, it would be worth $80,089.89 today based on a price of $23.92 for CELH at the time of writing.
<h3>Celsius Holdings's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738621815_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CELH

$1000 Invested In Celsius Holdings 10 Years Ago Would Be Worth This Much Today

Contracts

SATS

Tucows Subsidiary Wavelo Renews Four-year Contract To Provide Its Solutions For Echostar's Boost Mobile

Coca-Cola Consolidated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COKE#NASDAQ">COKE</a>) has outperformed the market over the past 10 years by 18.62% on an annualized basis producing an average annual return of 29.82%. Currently, Coca-Cola Consolidated has a market capitalization of $11.93 billion. 
Buying $100 In COKE: If an investor had bought $100 of COKE stock 10 years ago, it would be worth $1,365.83 today based on a price of $1361.46 for COKE at the time of writing.
<h3>Coca-Cola Consolidated's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738620909_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

COKE

Here's How Much $100 Invested In Coca-Cola Consolidated 10 Years Ago Would Be Worth Today

NewMarket Expects Continued Strength In Both Petroleum Additives And Specialty Materials Segments

BRBR

BellRing Brands Raises FY25 Net Sales Outlook From $2.24B - $2.32B To $2.26B - $2.34B (Est $2.295B)

Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) reported second-quarter financial results Monday after the bell. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/02/n43448785/clorox-reports-q2-fiscal-year-2025-results-updates-outlook">of the report</a>.
Q2 Earnings: Clorox reported fiscal second-quarter revenue of $1.69 billion, beating the consensus estimate of $1.63 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The household consumer products company reported adjusted earnings of $1.55 per share, beating analyst estimates of $1.41 per share.
Clorox said net sales decreased 15% on a year-over-year basis. Health and Wellness sales fell 13%, Household sales decreased 11%, Lifestyle sales were down 16% and International sales fell 12%. 
Gross margin increased 30 basis points to&nbsp;43.8%, up from&nbsp;43.5%&nbsp;in the prior year&#8217;s quarter. Net cash provided by operations year-to-date came in at $401 million, up from $173 million year-over-year. 
Clorox ended the period with $290 million of cash and cash equivalents. 
&#8220;We achieved better-than-expected results across sales, margin and EPS in the&nbsp;second quarter&nbsp;due to our strong demand creation plans, which also supported our share growth,&#8221; said&nbsp;Linda Rendle, chair and CEO of Clorox.
&#8220;We are further advancing our transformation as we embark upon a significant milestone with our Enterprise Resource Planning transition in the U.S., resulting in our updated outlook. I am confident that we are taking the right actions to deliver strong financial performance and long-term, profitable growth.&#8221;
Outlook: Clorox raised its full-year earnings forecast from a range of $6.65 to $6.90 per share to a new range of $6.95 to $7.35 per share versus estimates of $6.84 per share. The company also guided for 2025 net sales in a range of down 1% to up 2%. 
CLX Price Action: <a href="http://benzinga.com/quote/clx">Clorox shares</a> were down 2.28% after-hours, trading at $155.13 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43449997/nxp-semiconductors-reports-better-than-expected-q4-results-details">NXP Semiconductors Reports Better-Than-Expected Q4 Results: Details</a></li>
</ul>
Photo: Shutterstock.
&nbsp;

Clorox Stock Slides On Q2 Earnings

United Rentals has elected to withdraw and refile its Premerger Notification and Report Form, which was initially filed on January 16, 2025, to provide the FTC with additional time for review, given the abbreviated 15-day review period associated with cash tender offers. Upon such refiling, the 15-day waiting period under the HSR Act restarted, with the new waiting period expiring at 11:59 P.M., Eastern Time, on February 18, 2025.
 &nbsp;

HEES

United Rentals Reveals Notice Of Withdrawal And Refiling Of Premerger Notification And Report Form Under HSR Act In Connection With Pending Acquisition Of H&E Equipment Services

Offerings

CTCX

Carmell Files For Mixed Shelf Of Up To $100M - Filing

AVAV

AeroVironment Secures Third Delivery Order Totaling $288M Of Switchblade Loitering Munition Systems As Part Of US Army's Directed Requirement For Lethal Unmanned Systems

NewMarket (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEU#NYSE">NEU</a>) reported quarterly earnings of $11.56 per share. This is a 37.95 percent increase over earnings of $8.38 per share from the same period last year. The company reported $654.65 million in sales this quarter. This is a 1.76 percent increase over sales of $643.35 million the same period last year.

NewMarket Q4 2024 GAAP EPS $11.56 Up From $8.38 YoY, Sales $654.65M Up From $643.35M YoY

BellRing Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRBR#NYSE">BRBR</a>) reported quarterly earnings of $0.58 per share which beat the analyst consensus estimate of $0.48 by 20.83 percent. This is a 34.88 percent increase over earnings of $0.43 per share from the same period last year. The company reported quarterly sales of $532.90 million which beat the analyst consensus estimate of $525.17 million by 1.47 percent. This is a 23.82 percent increase over sales of $430.40 million the same period last year.

Earnings Beats

BellRing Brands Q1 2025 Adj EPS $0.58 Beats $0.48 Estimate, Sales $532.90M Beat $525.17M Estimate

A second major development in the tariff political drama came late Monday as the United States and Canada reached an agreement to pause Donald Trump&#8217;s proposed trade levies <a href="https://www.benzinga.com/topic/tariffs">&#8220;for at least 30 days.&#8221;</a>
Canadian Prime Minister Justin Trudeau announced the deal on social media platform X following a phone call with Trump. 
The tariff deal includes new border security commitments to combat fentanyl trafficking and organized crime, mirroring Trump's agreement with <a href="https://www.benzinga.com/government/regulations/25/02/43440692/us-mexico-agrees-on-one-month-tariffs-pause-stocks-rebound-peso-rallies">Mexican President Claudia Sheinbaum.</a>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I just had a good call with President Trump. Canada is implementing our $1.3 billion border plan — reinforcing the border with new choppers, technology and personnel, enhanced coordination with our American partners, and increased resources to stop the flow of fentanyl. Nearly…
&mdash; Justin Trudeau (@JustinTrudeau) <a href="https://twitter.com/JustinTrudeau/status/1886529228193022429?ref_src=twsrc%5Etfw">February 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<h3 class="wp-block-heading">Canada Rolls Out $1.3 Billion Border Plan</h3>
Trudeau outlined a $1.3 billion border reinforcement initiative featuring:
<ul>
<li>Deployment of nearly 10,000 frontline personnel equipped with new helicopters, surveillance technology and enhanced coordination with U.S. agencies.</li>
<li>The appointment of a fentanyl Czar to spearhead drug interdiction efforts.</li>
<li>Official designation of cartels as terrorist organizations to enable tougher enforcement measures.</li>
<li>The creation of a Canada-U.S. Joint Strike Force targeting organized crime, fentanyl networks and money laundering.</li>
<li>A $200 million intelligence directive to enhance monitoring and enforcement along the northern border.</li>
</ul>
&#8220;Proposed tariffs will be paused for at least 30 days while we work together,&#8221; the Canadian prime minister said. 
<h3 class="wp-block-heading">Markets React: Canadian Dollar Rallies, Equities Gain</h3>
The tariff deal gave a reprieve Canadian assets that were battered by heightened uncertainty earlier Monday. 
The Canadian dollar rallied, with the USD/CAD exchange rate dropping to 1.4391, down from 1.46 levels prior to the news.
Canadian equities also advanced in after-hours trading, with the iShares MSCI Canada Index Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EWC#NYSE">EWC</a>) rising over 1%.
Read Next.
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/43447339/trump-announces-us-sovereign-wealth-fund-hints-at-tiktok-ownership">Trump Orders US Sovereign Wealth Fund, Hints At TikTok Ownership: &#8216;I Have The Right To Do That&#8217;</a></li>
</ul>
Photo via Shutterstock.

Equities

Government

Regulations

Emerging Markets

Specialty ETFs

Politics

Forex

Economics

Markets

ETFs

Trump, Trudeau Strike Border Security Deal, Tariffs On Canada Paused For 'At Least 30 Days '

RBB Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBB#NASDAQ">RBB</a>) reported quarterly earnings of $0.25 per share which missed the analyst consensus estimate of $0.36 by 30.56 percent. The company reported quarterly sales of $28.71 million which beat the analyst consensus estimate of $28.12 million by 2.10 percent. This is a 13.18 percent decrease over sales of $33.06 million the same period last year.

Earnings Misses

RBB Bancorp Q4 2024 GAAP EPS $0.25 Misses $0.36 Estimate, Sales $28.71M Beat $28.12M Estimate

Providing a diverse range of perspectives from bullish to bearish, 12 analysts have published ratings on Oshkosh (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSK#NYSE">OSK</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $120.17, a high estimate of $137.00, and a low estimate of $109.00. Marking an increase of 2.23%, the current average surpasses the previous average price target of $117.55. 
<img src="https://www.benzinga.com/files/images/story/2025/1738620070_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Oshkosh. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steven Fisher</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$137.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Angel Castillo</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$110.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$127.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Tim Thein</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$118.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Steve Barger</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$132.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Steve Barger</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$113.00</td>
<td>-</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$109.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Kyle Menges</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$110.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$115.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$116.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Steven Fisher</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$125.00</td>
<td>$129.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Oshkosh. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Oshkosh compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Oshkosh's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Oshkosh's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/OSK/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Oshkosh analyst ratings.</a>
<h2>Discovering Oshkosh: A Closer Look</h2>
Oshkosh is the top producer of access equipment, specialty vehicles, and military trucks. It serves diverse end markets, where it is typically the market share leader in North America, or, in the case of JLG aerial work platforms, a global leader. The company had manufactured joint light tactical vehicles for the us Department of Defense. However, Oshkosh recently lost the JLTV recompete, bringing into focus its us Postal Service contract, which calls for the electrification of us postal vehicles. The company reports in three segments—access equipment (52% of revenue), defense (22%), and vocational (27%)—and generated $9.6 billion in revenue in 2023.
<h3>Oshkosh: Financial Performance Dissected</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Oshkosh faced challenges, resulting in a decline of approximately -4.3% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Oshkosh's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 5.84%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Oshkosh's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 3.71%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Oshkosh's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.58%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.23, Oshkosh adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Deep Dive Into Oshkosh Stock: Analyst Perspectives (12 Ratings)

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $273.0, with a high estimate of $286.00 and a low estimate of $265.00. This current average has increased by 3.1% from the previous average price target of $264.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1738620063_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Labcorp Holdings's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$271.00</td>
<td>$249.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$286.00</td>
<td>$293.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$265.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$270.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$271.00</td>
<td>$262.00</td>
</tr>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$275.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Labcorp Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Labcorp Holdings compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Labcorp Holdings's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Labcorp Holdings's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Labcorp Holdings analyst ratings.</a>
<h2>Get to Know Labcorp Holdings Better</h2>
Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Labcorp Holdings: Financial Performance Dissected</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3 months period, Labcorp Holdings showcased positive performance, achieving a revenue growth rate of 7.37% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Labcorp Holdings's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 5.16%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Labcorp Holdings's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.09%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.96%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Labcorp Holdings's debt-to-equity ratio is below the industry average at 0.94, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Laboratory Corporation Of America Holdings

Beyond The Numbers: 6 Analysts Discuss Labcorp Holdings Stock

In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on SAB Biotherapeutics (SABS – Research Report), with a price ...

SAB Biotherapeutics (SABS) Gets a Buy from Oppenheimer

Craig-Hallum analyst Albert Lowe maintained a Buy rating on SAB Biotherapeutics (SABS – Research Report) today and set a price target of $11.00. Th...

Craig-Hallum Remains a Buy on SAB Biotherapeutics (SABS)

SAB Biotherapeutics GAAP EPS of -$1.12

Oppenheimer analyst Leland Gershell maintained a Buy rating on SAB Biotherapeutics (SABS – Research Report) today and set a price target of $12.00....

Oppenheimer Sticks to Their Buy Rating for SAB Biotherapeutics (SABS)

The year is winding down, but the bull markets are still charging ahead, getting a boost from improved sentiment after the presidential election. W...

These 2 "Strong Buy" Penny Stocks Are Set to Triple (or more), Say Analysts

Craig-Hallum analyst Albert Lowe maintained a Buy rating on SAB Biotherapeutics (SABS – Research Report) today. The company's shares closed yesterd...

SAB Biotherapeutics (SABS) Gets a Buy from Craig-Hallum

SAB BIO announced positive topline data from a Phase 1 trial of SAB-142 in a single-ascending dose among healthy volunteers. The study met its prim...

SAB Biotherapeutics announces data from Phase 1 trial of SAB-142

In a report released today, Albert Lowe from Craig-Hallum maintained a Buy rating on SAB Biotherapeutics (SABS – Research Report). The company's sh...

In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on SAB Biotherapeutics (SABS – Research Report), with a price...

Strong Buy Recommendation for SAB-142: Promising Phase 1 Results and Future Market Potential in T1D Treatment

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Comments

SAB Biotherapeutics

Noticias

Últimas noticias sobre SAB Biotherapeutics (NASDAQ:SABS) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL